Abstract
Nipah virus (NiV) is a highly pathogenic, recently emerged paramyxovirus that has been responsible for sporadic outbreaks of respiratory and encephalitic disease in Southeast Asia. High case fatality rates have also been associated with recent outbreaks in Malaysia and Bangladesh. Although over two billion people currently live in regions in which NiV is endemic or in which the Pteropus fruit bat reservoir is commonly found, there is no approved vaccine to protect against NiV disease. This report examines the feasibility and current efforts to develop a NiV vaccine including potential hurdles for technical and regulatory assessment of candidate vaccines and the likelihood for financing.
Original language | English (US) |
---|---|
Pages (from-to) | 2971-2975 |
Number of pages | 5 |
Journal | Vaccine |
Volume | 34 |
Issue number | 26 |
DOIs | |
State | Published - Jun 3 2016 |
Keywords
- Live attenuated vaccine
- Nipah virus
- Soluble G protein
- Subunit vaccine
ASJC Scopus subject areas
- Molecular Medicine
- General Immunology and Microbiology
- General Veterinary
- Public Health, Environmental and Occupational Health
- Infectious Diseases